

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: KEI ROGER AOKI et al.

Examiner: GUPTA, Anish

Serial No.: 10/726,904

Group Art Unit: 1654

Filed: December 2, 2003

Confirmation No.: 4172

For: USE OF THE NEUROTOXIC  
COMPONENT OF A  
BOTULINUM TOXIN FOR  
TREATING VARIOUS  
DISORDERS AND CONDITIONS  
AND ASSOCIATED PAIN

Irvine, California

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


Applicant's provide with regard to the patent application entitled USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING VARIOUS DISORDERS AND CONDITIONS AND ASSOCIATED PAIN, filed herewith one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of documents submitted is set forth on the attached Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, their disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: June 1, 2007

  
Ronald C. Lundquist, Reg. No. 37,875

Please direct all inquiries and correspondence to:

Stephen Donovan  
Allergan, Inc.  
2525 Dupont Drive, T2-7H  
Irvine, California 92623-9534  
Tel: 714.246-4026  
Fax: 714.246-4249

**LIST OF ART CITED BY APPLICANT**

<b>ATTY. DOCKET:</b> 16952-CON1-CIP3 (BOT)	<b>SERIAL NO.:</b> 10/726,904
<b>APPLICANT:</b> AOKI et al.	<b>TITLE:</b> USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR TREATING VARIOUS DISORDERS AND CONDITIONS AND ASSOCIATED PAIN
<b>FILING DATE:</b> DECEMEBER 2, 2003	<b>GROUP:</b> 1654

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA						

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA						

**OTHER ART**

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	"Starkes Toxin hilft bei Blepharospasmus" (October 10, 1987).
	CB	"Botulinum-Toxin hilft bei Augenleiden" (December 1986).
	CC	Schantz, et al., "Quality of Botulinum Toxin for Human Treatment" <u>Botulinum and Tetanus Neurotoxins</u> , pp. 41-49, (1993).
	CD	Schantz, et al., "Preparation and Characterization of Botulinum Toxin Type A for Human Treatment" <u>Therapy with Botulinum Toxin</u> , pp. 657-659, (1994).
	CE	Schiavo, et al., "Tetanus and Botulism Neurotoxins: Isolation and Assay" <u>Methods Enzymol</u> , Vol. 248; pp. 643-652, (1995).
	CF	Zhang, et al., "Detection of Botulinum Neurotoxin's Enzymatic Activity of Type A Ghuncha Ambrin" <u>Faseb J.</u> , Vol. 18(8); 1 page, (2004).

EXAMINER \_\_\_\_\_ DATE CONSIDERED \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.